RIVIERA BEACH, Fla., May 19, 2017 /PRNewswire/ — Sancilio & Company, Inc. (SCI) announced the participation of members of the leadership and scientific team at the Scientific Sessions of the National Lipid Association (NLA) on May 20th, 2017, in Philadelphia, PA, where they will deliver several novel scientific presentations from the company’s current research.
The key findings from the research presented in this meeting, using Advanced Lipid Technologies™ (ALT®), further support enhanced bioavailability, overcoming food effect, and reduction of triglyceride levels after patients were treated with omega-3 fatty acids + ALT®. These presentations will update the research community on the clinical work being performed at SCI, in support of SCI’s late-stage development program, SC401, in Severe Hypertriglyceridemia.
„We are excited to share these data at such an important scientific event,” said Dr. Frederick D. Sancilio, PhD, President and CEO of SCI.
The following poster presentations are scheduled to be delivered Saturday, May 20th, 2017:
The NLA is a nonprofit multidisciplinary health care community that focuses on the prevention of dyslipemias and their associated cardiometabolic disorders. Its mission is to enhance the practice of lipid management in clinical medicine and enhance the efforts to reduce death and disability related to disorders of lipid metabolism in patients.
About Sancilio & Company, Inc.
Sancilio & Company, Inc. (SCI) is a fully integrated, specialty pharmaceutical company focused on developing, manufacturing and commercializing pharmaceutical products, including those based on our proprietary Advanced Lipid Technologies™ (ALT®) platform. SCI is pursuing treatments for sickle cell disease, short bowel syndrome and severe hypertriglyceridemia. We utilize our cGMP compliant facility to develop and manufacture our products. Our ALT® platform is designed to enhance the bioavailability, reduce the food effect and improve the efficacy of lipids and lipophilic active pharmaceutical ingredients (APIs). Our business model is to apply our ALT® platform to lipids or lipophilic APIs to create unique product candidates that address the disorders and diseases resulting from imbalances of lipids in the body. In addition to our primary focus of developing our proprietary products using the ALT® platform, we make use of, and license rights to, our proprietary ALT® platform and other technologies to third parties, providing both development and subsequent soft gelatin encapsulation services as required. More information is available at: www.sancilio.com.
SOURCE Sancilio & Company, Inc.